![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MIXL1 |
Gene summary for MIXL1 |
![]() |
Gene information | Species | Human | Gene symbol | MIXL1 | Gene ID | 83881 |
Gene name | Mix paired-like homeobox | |
Gene Alias | MILD1 | |
Cytomap | 1q42.12 | |
Gene Type | protein-coding | GO ID | GO:0001667 | UniProtAcc | Q9H2W2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
83881 | MIXL1 | HCC1 | Human | Liver | HCC | 4.54e-05 | 1.18e+00 | 0.5336 |
83881 | MIXL1 | HCC2 | Human | Liver | HCC | 1.10e-09 | 1.05e+00 | 0.5341 |
83881 | MIXL1 | HCC5 | Human | Liver | HCC | 3.62e-17 | 1.21e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00074921 | Liver | HCC | endoderm development | 43/7958 | 77/18723 | 1.24e-02 | 4.51e-02 | 43 |
GO:000166721 | Liver | HCC | ameboidal-type cell migration | 226/7958 | 475/18723 | 1.35e-02 | 4.81e-02 | 226 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MIXL1 | SNV | Missense_Mutation | novel | c.614N>G | p.Ser205Cys | p.S205C | Q9H2W2 | protein_coding | tolerated(0.14) | possibly_damaging(0.846) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
MIXL1 | SNV | Missense_Mutation | c.487N>T | p.Pro163Ser | p.P163S | Q9H2W2 | protein_coding | deleterious(0.03) | benign(0.212) | TCGA-EA-A6QX-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
MIXL1 | SNV | Missense_Mutation | c.353N>A | p.Arg118His | p.R118H | Q9H2W2 | protein_coding | deleterious(0.01) | probably_damaging(0.975) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
MIXL1 | SNV | Missense_Mutation | c.449N>A | p.Arg150Gln | p.R150Q | Q9H2W2 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
MIXL1 | SNV | Missense_Mutation | novel | c.706N>A | p.Ala236Thr | p.A236T | Q9H2W2 | protein_coding | tolerated(0.16) | benign(0.1) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MIXL1 | SNV | Missense_Mutation | rs769845658 | c.580G>A | p.Glu194Lys | p.E194K | Q9H2W2 | protein_coding | deleterious(0.03) | benign(0.003) | TCGA-B5-A11Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MIXL1 | SNV | Missense_Mutation | novel | c.559G>A | p.Val187Ile | p.V187I | Q9H2W2 | protein_coding | deleterious(0.01) | benign(0.15) | TCGA-E6-A2P9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MIXL1 | SNV | Missense_Mutation | novel | c.504N>A | p.Asn168Lys | p.N168K | Q9H2W2 | protein_coding | tolerated(0.27) | benign(0.045) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MIXL1 | SNV | Missense_Mutation | novel | c.280N>T | p.Ser94Cys | p.S94C | Q9H2W2 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-55-8096-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MIXL1 | SNV | Missense_Mutation | rs748533425 | c.406C>T | p.Pro136Ser | p.P136S | Q9H2W2 | protein_coding | tolerated_low_confidence(0.25) | benign(0.005) | TCGA-55-A4DF-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |